Abstract
Background: This study evaluated the effects of islet allotransplantation (ITx) on metabolic control utilizing a continuous glucose monitoring system (CGMS) and assessed its effectiveness as an indicator and predictor of graft dysfunction (GD). Methods: Glycemic control was assessed in 25 patients with type 1 diabetes mellitus (T1DM); 12 ITx recipients and 13 controls. Mean interstitial glucose, standard deviation (SD), glucose variability, and percentage of time in hyperglycemia (%GT >140 mg/dl), hypoglycemia (%GT <54 mg/dl), and normoglycemia (%GT 54-140 mg/dl) were measured in 72-hour time periods from CGMS recordings in the control group at baseline and in the ITx group at 3, 6, 9, 12, 15, and 18 months after ITx completion and were analyzed as predictors and indicators of GD. Hemoglobin A1c (HbA1c), 90-minute glucose after a mixed meal tolerance test, fasting C-peptide/glucose ratio, and insulin requirements were followed. Results: Compared to the control group, the percentage of time in hypoglycemia was significantly lower in the ITx group at all time points; time in normoglycemia was increased at all times except at 15 months; and time in hyperglycemia was significantly lower at 6, 9, 12, and 18 months. Mean glucose and glucose variability were significantly lower in the ITx group at all times except at 3 and 15 months, whereas HbA1c and 90-minute glucose were significantly lower in the ITx group at all time points. Mean glucose, SD, glucose variability, and %GT >140 mg/dl were significant as indicators but not as predictors of GD.
| Original language | English |
|---|---|
| Pages (from-to) | 221-228 |
| Number of pages | 8 |
| Journal | Journal of diabetes science and technology |
| Volume | 2 |
| Issue number | 2 |
| State | Published - Mar 1 2008 |
Fingerprint
Keywords
- Continuous glucose monitoring system
- Diabetes
- Graft dysfunction
- Islet transplantation
- Islets
- Metabolism
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Internal Medicine
- Bioengineering
- Biomedical Engineering
Cite this
Impact of islet transplantation on glycemic control as evidenced by a continuous glucose monitoring system. / Gorn, Lisa; Faradji, Raquel N.; Messinger, Shari; Monroy, Kathy; Baidal, David; Froud, Tatiana; Mastrototaro, John; Ricordi, Camillo; Alejandro, Rodolfo.
In: Journal of diabetes science and technology, Vol. 2, No. 2, 01.03.2008, p. 221-228.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of islet transplantation on glycemic control as evidenced by a continuous glucose monitoring system
AU - Gorn, Lisa
AU - Faradji, Raquel N.
AU - Messinger, Shari
AU - Monroy, Kathy
AU - Baidal, David
AU - Froud, Tatiana
AU - Mastrototaro, John
AU - Ricordi, Camillo
AU - Alejandro, Rodolfo
PY - 2008/3/1
Y1 - 2008/3/1
N2 - Background: This study evaluated the effects of islet allotransplantation (ITx) on metabolic control utilizing a continuous glucose monitoring system (CGMS) and assessed its effectiveness as an indicator and predictor of graft dysfunction (GD). Methods: Glycemic control was assessed in 25 patients with type 1 diabetes mellitus (T1DM); 12 ITx recipients and 13 controls. Mean interstitial glucose, standard deviation (SD), glucose variability, and percentage of time in hyperglycemia (%GT >140 mg/dl), hypoglycemia (%GT <54 mg/dl), and normoglycemia (%GT 54-140 mg/dl) were measured in 72-hour time periods from CGMS recordings in the control group at baseline and in the ITx group at 3, 6, 9, 12, 15, and 18 months after ITx completion and were analyzed as predictors and indicators of GD. Hemoglobin A1c (HbA1c), 90-minute glucose after a mixed meal tolerance test, fasting C-peptide/glucose ratio, and insulin requirements were followed. Results: Compared to the control group, the percentage of time in hypoglycemia was significantly lower in the ITx group at all time points; time in normoglycemia was increased at all times except at 15 months; and time in hyperglycemia was significantly lower at 6, 9, 12, and 18 months. Mean glucose and glucose variability were significantly lower in the ITx group at all times except at 3 and 15 months, whereas HbA1c and 90-minute glucose were significantly lower in the ITx group at all time points. Mean glucose, SD, glucose variability, and %GT >140 mg/dl were significant as indicators but not as predictors of GD.
AB - Background: This study evaluated the effects of islet allotransplantation (ITx) on metabolic control utilizing a continuous glucose monitoring system (CGMS) and assessed its effectiveness as an indicator and predictor of graft dysfunction (GD). Methods: Glycemic control was assessed in 25 patients with type 1 diabetes mellitus (T1DM); 12 ITx recipients and 13 controls. Mean interstitial glucose, standard deviation (SD), glucose variability, and percentage of time in hyperglycemia (%GT >140 mg/dl), hypoglycemia (%GT <54 mg/dl), and normoglycemia (%GT 54-140 mg/dl) were measured in 72-hour time periods from CGMS recordings in the control group at baseline and in the ITx group at 3, 6, 9, 12, 15, and 18 months after ITx completion and were analyzed as predictors and indicators of GD. Hemoglobin A1c (HbA1c), 90-minute glucose after a mixed meal tolerance test, fasting C-peptide/glucose ratio, and insulin requirements were followed. Results: Compared to the control group, the percentage of time in hypoglycemia was significantly lower in the ITx group at all time points; time in normoglycemia was increased at all times except at 15 months; and time in hyperglycemia was significantly lower at 6, 9, 12, and 18 months. Mean glucose and glucose variability were significantly lower in the ITx group at all times except at 3 and 15 months, whereas HbA1c and 90-minute glucose were significantly lower in the ITx group at all time points. Mean glucose, SD, glucose variability, and %GT >140 mg/dl were significant as indicators but not as predictors of GD.
KW - Continuous glucose monitoring system
KW - Diabetes
KW - Graft dysfunction
KW - Islet transplantation
KW - Islets
KW - Metabolism
UR - http://www.scopus.com/inward/record.url?scp=67651239780&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67651239780&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:67651239780
VL - 2
SP - 221
EP - 228
JO - Journal of diabetes science and technology
JF - Journal of diabetes science and technology
SN - 1932-2968
IS - 2
ER -